Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.38 |
| ▸ | GGH | Q92820 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7750537 | 0.77 | NAALAD2 (0.70) | MMP9NAALAD2GGHCYP1A2CYP2D6 | |
| SCHEMBL28224269 | 0.77 | KMT2A (0.49) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL5850168 | 0.76 | KMT2A (0.48) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL3448329 | 0.72 | KMT2A (0.64) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL3448327 | 0.72 | KMT2A (0.64) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL21461809 | 0.72 | HRH1 (0.49) | MMP2MMP9NAALAD2C3AR1 | |
| SCHEMBL16207519 | 0.72 | HRH1 (0.49) | MMP2MMP9NAALAD2C3AR1 | |
| SCHEMBL5283204 | 0.71 | KMT2A (0.56) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL1087101 | 0.71 | KMT2A (0.49) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL1086444 | 0.71 | KMT2A (0.49) | KMT2AMMP2MMP9NAALAD2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019183294-A1 | THERAPEUTIC CELL SYSTEMS AND METHODS FOR TREATING HOMOCYSTINURIA | RUBIUS THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-10340027-B2 | Identification of multi-modal associations between biomedical markers | KONINKLIJKE PHILIPS N.V. (NL) | 2019-07-02 | — | — | US | disclosed |
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | BP CORP NORTH AMERICA INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-7635572-B2 | Methods for conducting assays for enzyme activity on protein microarrays | Life Technologies Corporation (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090217398-A1 | METHODS TO IDENTIFY FAT AND LEAN ANIMALS USING CLASS PREDICTORS | HILL'S PET NUTRITION, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20050118665-A1 | Methods for conducting assays for enzyme activity on protein microarrays | PROTOMETRIX, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20040115629-A1 | Comprises nucleotide sequences coding polypeptide for treament of parkinson's, alzheimer's and cancer disorders; gene therapy | PANZER SCOTT R (US) | 2004-06-17 | — | — | US | disclosed |
| WO-2004023973-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | INCYTE CORPORATION (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040048253-A1 | Molecules for diagnostics and therapeutics | INCYTE CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-20040014087-A1 | Molecules for diagnostics and therapeutics | INCYTE CORPORATION (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1364015-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | Incyte Genomics, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207430-A1 | For diagnosis, therapy, and prevention of disorders related to aberrant expression | INCYTE GENOMICS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003062376-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | INCYTE GENOMICS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002097031-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | INCYTE GENOMICS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1259618-A2 | HUMAN ENZYME MOLECULES | Incyte Genomics, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002020754-A2 | Molecules for diagnostics and therapeutics | INCYTE GENOMICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1169469-A1 | HUMAN COLON CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES | Human Genome Sciences, Inc. (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001064896-A2 | HUMAN ENZYME MOLECULES | INCYTE GENOMICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000055351-A1 | HUMAN COLON CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES | HUMAN GENOME SCIENCES, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | POLN, POLM, POLI | KMT2A 2558/4885MMP2 930/4885MMP9 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.